An Middle East and Africa Genome Editing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CRISPR, TALEN

Middle East and Africa Genome Editing Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CRISPR, TALEN, Antisense, and Other), Application (Cell Line Engineering, Genetic Engineering, Diagnostic Applications, Drug Discovery, and Others), and End User (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Clinical Research Organizations)

The genome editing market in the Middle East & Africa is expected to grow from US$ 205.01 million in 2021 to US$ 609.86 million by 2028; it is estimated to grow at a CAGR of 16.9% from 2021 to 2028. Technological developments in healthcare IT allow artificial intelligence (AI) to manufacture CRISPR Systems. Developers working in the healthcare IT domain are engaged in analyzing the processes to control and monitor all the stages of product development. The focus is to develop technologies from discovering biomarkers to clinical trials and patient monitoring. A few companies have initiated implementing their expertise to use AI for digital manufacturing. In March 2019, Oxford Biomedica plc collaborated with Microsoft Research for R&D of cloud and machine learning to improve the production and quality of next-generation gene therapy vectors such as LentiVector. Under this collaboration, Oxford Biomedica utilized Microsoft’s Azure intelligent cloud platform to develop in silico models and innovative algorithms to advance the next-generation cell and gene delivery technology. Similarly, in June 2018, Celixir plc acquired Desktop Genetics to develop CRISPR-based gene editing. In August 2018, bluebird bio, Inc. and Gritstone Oncology, Inc. collaborated to develop and commercialize cell therapy products intended for cancer treatment. Under the agreement, Gritstone Oncology has utilized its proprietary EDGE artificial intelligence platform to analyze specific tumor types. EDGE AI platform has helped identify tumor-specific targets and natural T-cell receptors (TCRs) used as targets by bluebird bio to develop cell therapies. Further, Gritstone Oncology utilized those identified targets to conduct development, manufacturing, and commercial processes. Thus, such innovations in genome editing are enhancing market growth.

Economic uncertainties and ongoing conflicts are worsening the condition in the region. For instance, Iran was in a deep economic recession due to the US sanctions. Also, the major source of economic stabilization in Middle East countries is oil production and export. However, the recent COVID-19 pandemic caused turbulence to the economies of the Middle East. A sudden drop in domestic and external demand for goods and products, especially crude oil, and halted production due to labor shortage are major impacts observed in the region. The spread of COVID-19 in the region caused heavy burdens on healthcare professionals. The government and the regulatory agencies offered favorable support to the researchers and the market players to develop and explore genome-based technologies treatment and immunization of the population in the region. These factors are projected to have progressive impact on the market in the Middle East & Africa region.

The Middle East & Africa genome editing market is segmented into technology, application, and end user. Based on application, the market is segmented into cell line engineering, genetic engineering, diagnostic applications, drug discovery, and others. In 2021, genetic engineering segment held the largest share in the market. Cell line engineering is majorly done in laboratories, and it is performed to understand the basic biology behind the diseases and therapeutics. Cell line engineering provides benefits such as optimizing cell lines for the recombinant protein expression and characterization of the protein profile of genetically modified organisms. Cell line engineering enables the production of various industrial and commercial products that gain much more revenue as the products are produced per the desired requirement. Market players such as Horizon Discovery, Thermo Fisher Scientific, Lonza, Merck KGaA and Biognosys provide the products and services for cell line engineering. There are various advantages of the cell line engineering, such as cost-effective, easy to use, providing an unlimited supply of material, and bypassing ethical concerns associated with the use of animal and human tissues. In addition, cell line engineering has benefitted researchers for developing a vaccine, testing drug metabolism and cytotoxicity, antibody production, the study of gene function, generation of artificial tissues, and synthesis of biological compounds. Thus, the factors mentioned above are driving the growth of the genetic engineering segment in the market.

The overall Middle East & Africa genome editing market size has been derived using both primary and secondary sources. To begin the research process, exhaustive secondary research has been conducted using internal and external sources to obtain qualitative and quantitative information related to the market. The process also serves the purpose of obtaining overview and forecast for the Middle East & Africa genome editing market with respect to all the market segments. Also, multiple primary interviews have been conducted with industry participants to validate the data and to gain more analytical insights into the topic. The participants typically involved in this process include industry experts such as VPs, business development managers, market intelligence managers, and national sales managers—along with external consultants such as valuation experts, research analysts, and key opinion leaders—specializing in the Middle East & Africa genome editing market. THERMO FISHER SCIENTIFIC INC., MERCK KGaA, Lonza, Horizon Discovery Group plc., GenScript, New England Biolabs, Eurofins Scientific, and CRISPR Therapeutics are among the leading companies in the market.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East & Africa genome editing market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Middle East & Africa genome editing market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Middle East & Africa market trends and outlook coupled with the factors driving the genome editing market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution